We used a dual-probe evaluation and considering the combined signals of HER2 (a red signal) and CRYBA1 (a green signal), 2 (2/16; 12.5%) carcinomas were amplified (Figure 3A), and 14 (14/16; 87.5%) carcinomas were not amplified (Figure 3B). Here, ERBB2 is linked to carcinoma.